Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FABP7 | O15540 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6642777 | 0.91 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MAPT | |
| SCHEMBL3560869 | 0.88 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19MAPT | |
| SCHEMBL4756904 | 0.87 | RAB9A (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MAPT | |
| SCHEMBL17307104 | 0.86 | NPC1 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MAPT | |
| SCHEMBL10917021 | 0.85 | FABP7 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL280126 | 0.85 | FABP7 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL6666657 | 0.85 | FABP7 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL3096459 | 0.85 | POLB (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3409075 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MAPT | |
| SCHEMBL13287204 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103814-A1 | IRREVERSIBLE FAP INHIBITOR AND USE THEREOF | 南京科络思生物科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| CN-110256489-B | Preparation method of alkyl phosphonyl | 苏州大学 | 2022-03-08 | — | — | CN | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2822942-B1 | BENZODIOXANES FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| EP-0828754-B1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040254178-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004094379-A2 | 3-PHENYL-4- (PYRIMIDIN-2-YL) -6- (PIPERIDIN-4-YL) DERIVATIVES AND RELATED COMPOUNDS AS TNF-ALPHA AND IL-1 INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1392686-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003099808-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2002096907-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-05 | — | — | WO | disclosed |
| EP-1115731-A2 | NOVEL PYRANOSES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000014097-A2 | NOVEL PYRANOSES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-16 | — | — | WO | disclosed |
| US-5936089-A | PIPERIDINE DERIVATIVES; BONE DISORDERS; OBESITY; AGING; CACHEXIA ASSOCIATED WITH AIDS AND CANCER | PFIZER INC (US) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885NPC1 516/4885RAB9A 1694/4885 |
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | NRDC, NUCB2, ASNS | SMN1; SMN2 1149/4885NPC1 961/4885RAB9A 1925/4885 |
| US-20040254178-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MAPT, MUSK | SMN1; SMN2 9/4885NPC1 2806/4885RAB9A 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.